Welcome back to Plenary Session. This is the podcast at the intersection of medicine,

oncology, and health policy. Today we're back with Code Break 200's been published in The Lancet.

People are praising it. Somebody said, don't throw the baby out with the bathwater. Well,

it turns out it's all getting thrown out. This is a god-awful study. It's piss poor. It's

derelict. It's horrific.

I've seen so many problems in studies.

It's rare that you get them all lined up at once.

Code Break 200.

We're going to break it down.

I don't know how long this video is.

It's probably going to be pretty long because I found so much junk in this study. And by the end of it, I think you will feel like me that this

represents the follow oncology. I mean, it's emblematic of how our profession is rotting.

We're rotting from the inside. We're debuting drugs that cost $15,000 per month, and we don't

have any good data for what we're doing. We're running

horrific trials that squander the participation of patients. Anyway, I'm getting ahead of myself.

Let me get into this one step at a time. So ToraSib versus dosataxil, second line and beyond,

non-small lung cancer with KRAS G12C. You know it. I hope that we know a lot of things that KRASG12C use

tends to be mutually exclusive with other driving mutations. I hope we know that. I hope we know

that this is one of the few that's already secured a ladder line approval. This is the

randomized confirmatory trial to Code Break 100 where they had some response rate. This is an

important study. We talked about it in press release.

I've already published an article on it, but yet the saga continues.

...